Drug assessment in the Ebola virus disease epidemic in west Africa.
暂无分享,去创建一个
P. Horby | Y. Yazdanpanah | Y. Lévy | V. Nguyen | J. van Griensven | J. Dunning | J. Delfraissy | F. Mentré | D. Sissoko | J. Malvy
[1] M. Altfeld,et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.
[2] G. Apolone,et al. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? , 2015, The Lancet Infectious Diseases.
[3] John Whitehead,et al. Evaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease , 2015, PLoS medicine.
[4] M. Egger,et al. Effi cacy and eff ectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination cluster-randomised trial , 2015 .
[5] Tom Fletcher,et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. , 2015, The New England journal of medicine.
[6] Rachel S. G. Sealfon,et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. , 2014, The New England journal of medicine.
[7] D P Byar,et al. Design considerations for AIDS trials. , 1990, The New England journal of medicine.